Susquehanna International Group, LLP Cardiff Oncology, Inc. Put Options Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$2.05 - $2.77 $19,885 - $26,869	9,700 Added 36.19%	36,500 $97,000
Q2 2024 Aug 15, 2024	BUY	$2.22 - $5.89 $16,206 - $42,997	7,300 Added 37.44%	26,800 $59,000
Q1 2024 May 07, 2024	SELL	$1.46 - $5.91 $12,410 - $50,235	-8,500 Reduced 30.36%	19,500 $104,000
Q4 2023 Feb 14, 2024	SELL	$0.96 - $1.55 $18,720 - $30,225	-19,500 Reduced 41.05%	28,000 $41,000
Q3 2023 Nov 14, 2023	BUY	$1.38 - $2.18 $65,550 - $103,550	47,500 New	47,500 $66,000
Q1 2023 May 16, 2023	BUY	$1.45 - $2.09 $61,045 - $87,989	42,100 Added 276.97%	57,300 $94,000
Q4 2022 Feb 14, 2023	SELL	$1.22 - $1.66 $35,990 - $48,970	-29,500 Reduced 66.0%	15,200 $21,000
Q3 2022 Nov 14, 2022	BUY	$1.54 - $3.21 $10,164 - $21,186	6,600 Added 17.32%	44,700 $69,000

12.3M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $184M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.